Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DAP000319

Drug Information
NameFulvestrant
Synonyms7alpha-[9[(4,4,5,5,5-Pentafluropentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene-3, 17 beta diol; (7alpha,17beta)-7-{9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl}estra-1,3,5(10)-triene-3,17-diol; CHEMBL1358; Fulvestrant (JAN/USAN/INN); Ici 182780; ICI 182,780; S1191_Selleck; I06-1109; ZM-182780; AC1L2XEN; NCGC00164789-02; BIDD:ER0348; NSC719276; nchembio.76-comp5; Faslodex(ICI 182,780); LS-64781; Faslodex, ICI 182780, Fulvestrant; HMS2090N22; 7-(9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)estra-1,3,5(10)-triene-3,17-diol; ZD 182780; AC-4693; (7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; DB00947; ICI-182780; HSDB 7658; CCRIS 8741; Fulvestrant [USAN]; UNII-22X328QOC4; C32H47F5O3S; ZD-182780; 129453-61-8; AstraZeneca brand of fulvestrant; 7alpha-(9-((4,4,5,5,5,-Pentafluoropentyl)sulfinyl)nonyl)estra-1,3,5(10)-triene-3,17beta-diol; CHEBI:404798; C070081; D01161; ZM 182780; 7alpha-(9-((4,4,5,5,5-Pentafluoropentyl)sulfinyl)nonyl)estra-1,3,5(10)-triene-3,17beta-diol; BIDD:PXR0136; CID104741; nchembio.168-comp5; Faslodex; Fulvestrant; ICI 182,789; ZD-9238; (7R,8S,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl) nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; (7R,13S,17S)-13-methyl-7-(9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol; Estra-1,3,5(10)-triene-3,17-diol, 7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-, (7alpha,17beta)-; Faslodex (TN); nchembio775-comp4
Trade NameFaslodex
CompanyAstraZeneca
IndicationBreast CancerApproved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C32H47F5O3S/c1-30-17-15-26-25-12-11-24(38)21-23(25)20-22(29(26
)27(30)13-14-28(30)39)10-7-5-3-2-4-6-8-18-41(40)19-9-16-31(33,34)
32(35,36)37/h11-12,21-22,26-29,38-39H,2-10,13-20H2,1H3/t22-,26-,2
7+,28+,29-,30+,41?/m1/s1
InChIKeyVWUXBMIQPBEWFH-WCCTWKNTSA-N
Canonical SMILESCC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F    
Isomeric SMILESC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@@H](CC4=C3C=CC(=C4)O)
CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F
Therapeutic ClassAntineoplastic Agents
CAS NumberCAS 129453-61-8
FormulaC32H47F5O3S
PubChem Compound IDCID 104741.
PubChem Substance IDSID 534986.
ChEBI31638;
SuperDrug ATC IDL02BA03
SuperDrug CAS ID129453618;
TargetEstrogen receptorAntagonist[2]
Ref 1Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20. To Reference
Ref 2Beta3-tubulin is induced by estradiol in human breast carcinoma cells through an estrogen-receptor dependent pathway. Cell Motil Cytoskeleton. 2009 Jul;66(7):378-88. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543